Altium Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Altium Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-253,000	Closed	-$1.83M	–	145
2022 Q1	$1.83M	Buy	253,000 +53,000	+27%	+$521K	0.61%	61
2021 Q4	$3.27M	Hold	200,000	–	–	0.9%	44
2021 Q3	$1.99M	Hold	200,000	–	–	0.52%	72
2021 Q2	$2M	Hold	200,000	–	–	0.46%	85
2021 Q1	$1.99M	Buy	+200,000	New	+$2.07M	0.55%	77

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Altium Capital Management's PRDS Position: Q2 2022 in Review

Altium Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q2 2022, closing a stake of 253,000 shares — an estimated $1.83M sold.

Altium Capital Management first reported a position in PRDS in Q1 2021 and held it in 5 quarters. The position peaked at $3.27M in Q4 2021. 69 funds tracked by Wall St. Rank hold PRDS as of Q2 2022.

Altium Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Altium Capital Management sold 253,000 Pardes Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1.83M.
Altium Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Altium Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $3.27M in Q4 2021.
69 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q2 2022.

Based on Altium Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.